Exact Sciences achieved 10% YoY revenue growth in Q4 2024, reaching $713.42M. Screening revenue grew by 14%, while Precision Oncology revenue remained flat. However, an $838M impairment charge led to a substantial net loss of $864.59M, significantly higher than the prior year's loss of $49.77M. Adjusted EBITDA improved to $75.38M with an 11% margin.
Total revenue grew 10% YoY to $713.42M.
Screening revenue increased by 14%, driven by Cologuard.
Net loss widened to $864.59M due to an $838M impairment charge.
Adjusted EBITDA rose to $75.38M with an 11% margin.
Exact Sciences expects revenue growth between 9%-12% in 2025, driven by new product launches and expanded screening adoption. Adjusted EBITDA is projected to improve, indicating better profitability.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance